Heritable Thoracic Aortic Disease
Definition
Heritable thoracic aortic disease (HTAD) is aortic aneurysm or dissection attributable to an inherited genetic predisposition — either syndromic (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner) or non-syndromic (familial, often with an identified variant in ACTA2, MYH11, MYLK, PRKG1, TGFBR1/2, SMAD3 or LOX). Its clinical importance is that the thresholds, growth rates and family obligations differ from sporadic disease, and that the specific gene changes the threshold. (sources/AD-AHA-2022, rating: very high)
Key Concepts
Why it is a separate category
- Heritable disease dissects younger, at smaller diameters, and grows faster — Marfan roots grow at 0.26 cm/year versus as little as 0.01 cm/year in sporadic tricuspid aortas. (sources/AD-AHA-2022)
- The growth trigger for intervention is lower: ≥0.3 cm in one year in HTAD, versus ≥0.5 cm in one year or ≥0.3 cm/year over two consecutive years in sporadic disease.
- The repair threshold is lower and is indexed to the gene, not just to the diameter.
- Family members are at risk even when the proband is not. This is the category in which cascade screening finds asymptomatic aneurysms that would otherwise present as dissection.
Genetic testing and family screening
- Take a three-generation family history in anyone with an aortic root or ascending aneurysm, or a dissection — covering thoracic aortic disease, unexplained sudden death, and peripheral or intracranial aneurysms (I/B).
- Offer genetic testing where there is a family history or features suggesting HTAD (I/B). A pathogenic or likely pathogenic variant is not required for management, but it changes counselling and cascade testing.
- Cascade testing of at-risk biological relatives is recommended where a variant is found (I/B), and irrespective of age in the ESC formulation (I/C) — a deliberate departure from the usual practice of starting testing in adulthood (sources/AD-PAD-ESC-2024, rating: very high).
- Where no variant is identified, screen relatives by imaging anyway (I/B for first-degree relatives of any aortic root/ascending aneurysm or dissection; I/C where HTAD is suspected but no variant found).
- Record the aortic diameter in the operative note at type A dissection repair (I) — this is what allows the affected relatives' management to be informed, and it is routinely omitted.
Thresholds by syndrome
| Syndrome | Repair threshold | Class |
|---|---|---|
| Marfan | Root ≥50 mm | I/B |
| Marfan with additional risk features | ≥45 mm | IIa |
| Marfan, area/height ratio | ≥10 cm²/m | IIa |
| Loeys-Dietz, TGFBR1/2 or SMAD3 | Root ≥45 mm; arch/descending/abdominal ≥45 mm (IIb) | IIa |
| Loeys-Dietz, TGFB2/3 | ≥45 mm before pregnancy | IIa |
| Non-syndromic HTAD, no identified gene | Gene/diameter guided by affected relatives' event diameters; ~45 mm where that information is unavailable and there are high-risk features | I–IIa |
| ACTA2 | ~45 mm (lower, ~42 mm, with risk features) | IIa/IIb |
| PRKG1 | ~42 mm (~40 mm with risk features) | IIb |
| Turner syndrome | ASI ≥2.5 cm/m² plus risk factors | IIa |
| Vascular Ehlers-Danlos | Individualised — tissue fragility dominates; celiprolol first, surgery deferred | IIa |
- The gene-specific numbers above 4.2 cm are not interchangeable. A PRKG1 dissection at 40 mm and an ACTA2 dissection at 44 mm mean the family's threshold is that number minus a margin, not the population's 50 mm.
- Measure and report an index in HTAD — ASI, AHI or z-score (I/C). Absolute diameter alone is not adequate.
Medical therapy
- Marfan: beta-blocker or ARB at maximal tolerated dose, Class I, Level A — the only Class I/A medical recommendation in the entire aortopathy section. (sources/AD-AHA-2022)
- Both together is reasonable (IIa) in Marfan and should be considered in Loeys-Dietz (IIa/A per ESC).
- Vascular Ehlers-Danlos: celiprolol should be considered (IIa/B) (sources/AD-PAD-ESC-2024) — the one syndrome with a specific drug recommendation.
- Angiotensin receptor blockade does not replace beta-blockade, and the trial evidence for ARB comes from Marfan specifically; extrapolation to other HTAD is by analogy.
- Fluoroquinolones should be avoided where an alternative exists — associated with increased dissection and aneurysm risk.
Surveillance
- Marfan: TTE at diagnosis, again at 6 months to establish growth rate, then annually; CT or MRI of the whole thoracic aorta at baseline; after root replacement, imaging annually for 2 years then every 2 years; abdominal aorta every 3–5 years. Complete vascular imaging at first evaluation then every 3–5 years if stable.
- Loeys-Dietz: baseline head-to-pelvis MRI or CT (I); TTE every 6–12 months; head-to-pelvis imaging every 1–3 years; cerebral artery surveillance every 2–3 years. Loeys-Dietz is a whole-arterial-tree disease, not an aortic one.
- Turner: TTE and cardiac MRI at diagnosis, with explicit assessment for bicuspid valve, root/ascending dilatation, coarctation and other congenital defects (I). ASI >2.3 cm/m² prompts at least annual imaging.
- Vascular Ehlers-Danlos: imaging of the aorta and peripheral arteries at baseline, and non-invasive imaging only — catheter angiography is avoided because of tissue fragility.
Pregnancy
- Preconception imaging and counselling for all aortopathies (I), with a maternal–fetal medicine specialist and cardiologist managing the pregnancy.
- Surgery before pregnancy: Marfan root >45 mm (I), 40–45 mm may be considered (IIb); non-syndromic HTAD ≥45 mm (I); Loeys-Dietz TGFB2/3 ≥45 mm (IIa) and TGFBR1/2 or SMAD3 ≥40 mm (IIb); Turner ASI ≥2.5 cm/m² (I).
- Beta-blocker throughout pregnancy and postpartum (I). ARBs are contraindicated in pregnancy (III) — the one place where the Marfan medical recommendation must be withdrawn.
- Delivery: vaginal if the diameter is <40 mm (I); caesarean reasonable at ≥45 mm (IIa); caesarean after chronic dissection (I).
- Acute type A dissection in the third trimester: caesarean immediately followed by aortic surgery (I). In the first or second trimester: aortic surgery with fetal monitoring (I).
Activity and counselling
- Avoid intense isometric exercise, burst exertion, Valsalva and collision sports (I). This is a Class I lifestyle recommendation, which is unusual and reflects the mechanism.
- Regular moderate aerobic exercise is recommended for most Marfan patients (I), with intensity informed by aortic diameter — the guideline is not asking for inactivity.
- Screen for anxiety, depression and PTSD in significant aortic disease (IIa), and provide postoperative cardiac rehabilitation (I).
Contradictions / Open Questions
- The evidence for gene-specific thresholds is retrospective and thin. The ACTA2 and PRKG1 numbers come from family series, not trials, and the guidelines grade them IIa/IIb while still expecting them to be used.
- Cascade testing irrespective of age (ESC) conflicts with the common practice of deferring predictive testing in children, and neither guideline discusses the ethical and insurance consequences.
- Marfan's Class I/A status for beta-blockers or ARB rests on a small number of trials, one of which (the ARB trials) was partly negative on the primary endpoint; the recommendation survived on pooled and secondary analyses.
- Vascular Ehlers-Danlos management is almost entirely expert opinion, and the celiprolol trial was small, single-centre and not replicated.
- Loeys-Dietz is a moving target — the phenotype is being split by gene as sequencing becomes routine, and the thresholds have not kept pace.
- No HTAD-specific data exist for the newer aortic drugs (finerenone, SGLT2 inhibitors, statins) that are being studied in sporadic aneurysm.
Connections
- Related to entities/Marfan-Syndrome — the most detailed syndrome page in the wiki
- Related to entities/Bicuspid-Aortic-Valve — heritable, but managed on its own phenotype-based thresholds
- Related to concepts/Thoracic-Aortic-Aneurysm — the sporadic counterpart, with the thresholds this page overrides
- Related to concepts/Acute-Aortic-Syndrome — the event this page exists to prevent, and often the presentation that first identifies a family
- Related to concepts/Prepregnancy-Cardiovascular-Health — shared preconception counselling
- Related to concepts/Cardiogenetic-Centers — where genetic testing and counselling are delivered